Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-27

Immunome (IMNM)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$7,682,601
Clay Siegall total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
98.44%
Say-on-pay support, latest vote
Companies that benchmark against IMNM
2 companies name IMNM as a compensation peer

Each company listed discloses IMNM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IMNM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Clay Siegall$735,000$0$0$6,272,810$661,500$0$13,291$7,682,601
President, Chief Executive Officer and Chairman of the Board
Max Rosett472,500001,623,090278,8000411,1672,785,557
Chief Financial Officer
Robert Lechleider530,300001,897,525307,600012,1932,747,618
Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Clay Siegall$7,682,601
Max Rosett2,785,557
Robert Lechleider2,747,618

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jean Jacques BienaimeDirector2026-05-15A5,000$21$103,500CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D10,00019194,100CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A6,00019116,880CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D500199,720CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A1,0001919,270CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A3,5001968,110CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
James BoylanDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Isaac BarchasDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Carol SchaferDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Philip WagenheimDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Sandra M. SwainDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,000181,093,800CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15A60,000163,000CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D14,42021297,917Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D40,58020793,745Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25A55,0009480,150CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D55,00000Derivative, Class A CommonForm 4 ↗
Isaac BarchasDirector2026-06-30D75,665221,691,113Common, indirectForm 4 ↗
Isaac BarchasDirector2026-06-30D101,050212,134,176Common, indirectForm 4 ↗
Isaac BarchasDirector2026-06-30D24,33523567,736Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,21423369,031Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D22,71422498,572Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D55,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02A55,0009480,150CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,07223376,728Common, open-market saleForm 4 ↗
Isaac BarchasDirector2026-07-06D16,90624409,125Common, indirectForm 4 ↗
Isaac BarchasDirector2026-07-06D83,094242,003,396Common, indirectForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07A1,0921314,109CommonForm 4 ↗
Dividend-equivalent accruals2026-07-071,0921 insider, 1 accrual row
Kinney HornCHIEF BUSINESS OFFICER2026-07-07D1,0922527,300CommonForm 4 ↗
Clay SiegallDirector2026-07-23A360,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A54,00000RSUForm 4 ↗
Max RosettChief Financial Officer2026-07-23A47,25000RSUForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A38,25000RSUForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A38,25000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A38,25000RSUForm 4 ↗
Clay SiegallDirector2026-07-23A180,00000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A108,00000Derivative, Class A CommonForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-07-23A94,50000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A31,25000RSUForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A62,50000Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 46 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Jean Jacques BienaimeDirector2026-05-15A5,000$21$103,500CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D10,00019194,100CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A6,00019116,880CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05D500199,720CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A1,0001919,270CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-05A3,5001968,110CommonForm 4 ↗
Jean Jacques BienaimeDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
James BoylanDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Isaac BarchasDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Carol SchaferDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Philip WagenheimDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Sandra M. SwainDirector2026-06-10A9,89700Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,000181,093,800CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15A60,000163,000CommonForm 4 ↗
Max RosettChief Financial Officer2026-06-15D60,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D14,42021297,917Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D40,58020793,745Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25A55,0009480,150CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-06-25D55,00000Derivative, Class A CommonForm 4 ↗
Isaac BarchasDirector2026-06-30D75,665221,691,113Common, indirectForm 4 ↗
Isaac BarchasDirector2026-06-30D101,050212,134,176Common, indirectForm 4 ↗
Isaac BarchasDirector2026-06-30D24,33523567,736Common, indirectForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,21423369,031Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D22,71422498,572Common, open-market saleForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D55,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02A55,0009480,150CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-02D16,07223376,728Common, open-market saleForm 4 ↗
Isaac BarchasDirector2026-07-06D16,90624409,125Common, indirectForm 4 ↗
Isaac BarchasDirector2026-07-06D83,094242,003,396Common, indirectForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07A1,0921314,109CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07D1,09200Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-07D1,0922527,300CommonForm 4 ↗
Clay SiegallDirector2026-07-23A360,00000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A54,00000RSUForm 4 ↗
Max RosettChief Financial Officer2026-07-23A47,25000RSUForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A38,25000RSUForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A38,25000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A38,25000RSUForm 4 ↗
Clay SiegallDirector2026-07-23A180,00000RSUForm 4 ↗
Philip TsaiChief Technical Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Robert LechleiderChief Medical Officer2026-07-23A108,00000Derivative, Class A CommonForm 4 ↗
Sandra G. StonemanCHIEF LEGAL OFFICER & GC2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Max RosettChief Financial Officer2026-07-23A94,50000Derivative, Class A CommonForm 4 ↗
Jack HigginsChief Scientific Officer2026-07-23A76,50000Derivative, Class A CommonForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A31,25000RSUForm 4 ↗
Kinney HornCHIEF BUSINESS OFFICER2026-07-23A62,50000Derivative, Class A CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Clay SiegallOPTION$6,272,810
Max RosettOPTION1,623,090
Robert LechleiderOPTION1,897,525
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Clay Siegall$0$0$6,272,8100.0%
Max Rosett001,623,0900.0%
Robert Lechleider001,897,5250.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Robert LechleiderOption242,00010.6
Max RosettOption18,12514.4
Clay SiegallOption533,33412.92
Max RosettOption91,14616.57
Max RosettOption8,3661.05
Robert LechleiderOption133,33412.92
Max RosettOption126,66712.92
Clay SiegallOption800,00010.6
Clay SiegallOption979,4955.91
Max RosettOption207,00010.6
Robert LechleiderOption183,3348.73
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation program is designed to align pay with Company performance and long-term stockholder value creation.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0990,908,4361,442,11631,01498.44%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0998.44%a

a. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Isaac Barchas, J.DIndependent · Lead Independent Director · Compensation · Nominating and Corporate Governance (Chair)$75,000$0$135,000$0$0$210,000
Carol SchaferIndependent · Audit (Chair) · Nominating and Corporate Governance60,0000135,00000195,000
James BoylanIndependent · Compensation (Chair) · Nominating and Corporate Governance55,0000135,00000190,000
Jean-Jacques BienaimIndependent · Audit · Compensation52,5000135,00000187,500
Sandra Swain, M.DIndependent · Audit47,5000135,00000182,500
Philip WagenheimIndependent · Compensation40,0000135,00000175,000
Clay Siegall, Ph.DEmployee director · Board Chair00000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$135,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)7,500 / 5,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$330,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$330,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Immunome2025Clay Siegall$735,000$0$6,272,810$661,500$7,682,601

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Clay SiegallDEF 14A2026-04-240001140361-26-016685Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 7,682,601. Filing ↗machine: r2 · c21 · span 416484–416493
2Section 01, Max RosettDEF 14A2026-04-240001140361-26-016685Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 2,785,557. Filing ↗machine: r4 · c21 · span 424106–424115
3Section 01, Robert LechleiderDEF 14A2026-04-240001140361-26-016685Section “Fiscal Year 2025 Summary Compensation Table” · page 27. As printed: 2,747,618. Filing ↗machine: r5 · c21 · span 428410–428419
4Section 03, Clay Siegall OPTIONDEF 14A2026-04-240001140361-26-016685Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r2 · c12 · span 414755–414764
5Section 03, Max Rosett OPTIONDEF 14A2026-04-240001140361-26-016685Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r4 · c12 · span 422704–422713
6Section 03, Robert Lechleider OPTIONDEF 14A2026-04-240001140361-26-016685Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t63 · r5 · c12 · span 426795–426804
7Section 07, pay ratio10-K2026-03-030001193125-26-088172Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Isaac Barchas, J.DDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 210,000. Filing ↗machine: t97 · r2 · c9 · span 658494–658501
9Section 08, Carol SchaferDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 195,000. Filing ↗machine: t97 · r3 · c9 · span 660217–660224
10Section 08, James BoylanDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 190,000. Filing ↗machine: t97 · r5 · c9 · span 663957–663964
11Section 08, Jean-Jacques BienaimDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 187,500. Filing ↗
12Section 08, Sandra Swain, M.DDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 182,500. Filing ↗machine: t97 · r6 · c9 · span 665955–665962
13Section 08, Philip WagenheimDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 175,000. Filing ↗machine: t97 · r7 · c9 · span 667584–667591
14Section 08, Clay Siegall, Ph.DDEF 14A2026-04-240001140361-26-016685Section “Director Compensation”. As printed: 0. Filing ↗
15Section 02, Jean Jacques Bienaime 2026-05-15Form 42026-05-190001221590-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Jean Jacques Bienaime 2026-06-05Form 42026-06-090001221590-26-000015Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Jean Jacques Bienaime 2026-06-10Form 42026-06-120001221590-26-000018Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, James Boylan 2026-06-10Form 42026-06-120001953094-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Isaac Barchas 2026-06-10Form 42026-06-120001808343-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Carol Schafer 2026-06-10Form 42026-06-120001272181-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Philip Wagenheim 2026-06-10Form 42026-06-120001405684-26-000003Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Sandra M. Swain 2026-06-10Form 42026-06-120001908755-26-000001Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Max Rosett 2026-06-15Form 42026-06-170001994071-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Max Rosett 2026-06-15Form 42026-06-170001994071-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Max Rosett 2026-06-15Form 42026-06-170001994071-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Robert Lechleider 2026-06-25Form 42026-06-290001997584-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Isaac Barchas 2026-06-30Form 42026-07-020001808343-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Isaac Barchas 2026-06-30Form 42026-07-020001808343-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Isaac Barchas 2026-06-30Form 42026-07-020001808343-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Robert Lechleider 2026-07-02Form 42026-07-070001997584-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, Isaac Barchas 2026-07-06Form 42026-07-070001808343-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Isaac Barchas 2026-07-06Form 42026-07-070001808343-26-000007Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Kinney Horn 2026-07-07Form 42026-07-090001831215-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Kinney Horn 2026-07-07Form 42026-07-090001831215-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Kinney Horn 2026-07-07Form 42026-07-090001831215-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Clay Siegall 2026-07-23Form 42026-07-270001167496-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Robert Lechleider 2026-07-23Form 42026-07-270001997584-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Max Rosett 2026-07-23Form 42026-07-270001994071-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Jack Higgins 2026-07-23Form 42026-07-270001993684-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Sandra G. Stoneman 2026-07-23Form 42026-07-270001831144-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Philip Tsai 2026-07-23Form 42026-07-270002026600-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Clay Siegall 2026-07-23Form 42026-07-270001167496-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Philip Tsai 2026-07-23Form 42026-07-270002026600-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Robert Lechleider 2026-07-23Form 42026-07-270001997584-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Sandra G. Stoneman 2026-07-23Form 42026-07-270001831144-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Max Rosett 2026-07-23Form 42026-07-270001994071-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Jack Higgins 2026-07-23Form 42026-07-270001993684-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Kinney Horn 2026-07-23Form 42026-07-270001831215-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Kinney Horn 2026-07-23Form 42026-07-270001831215-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
61Section 06, 2026 voteForm 8-K2026-06-120001193125-26-269383Item 5.07 · say-on-pay result. As reported: 98.44% (votes for as printed: 90,908,436). Filing ↗
62Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
63Section 09b board cost (computed)ComputedcomputedCash 330,000 + equity 0 + all other 0 = 330,000, summed across the director compensation table rows.machine: formula: Σ = 330,000
64Immunome (subject), Section 10b CEO totalDEF 14A2026-04-240001140361-26-016685CEO total compensation as printed in Immunome's own proxy. As printed: 7,682,601. Filing ↗machine: r2 · c21 · span 416484–416493